Population genomic screening for desmosome variants associated with arrhythmogenic right ventricular cardiomyopathy (ARVC) may facilitate early disease detection and protective intervention. The ...

Background Regular intensive physical activity is associated with non-pathological changes in cardiac morphology. Differential diagnosis with arrhythmogenic right ventricular cardiomyopathy (ARVC) ...

Lexeo Therapeutics, Inc.’s LXEO share price has dipped by 11.51%, which has investors questioning if this is right time to ...

New Mayo Clinic research connects energy drinks to cardiac emergencies in people with heart conditions. Learn who's at risk ...

"We were created to need each other. We always say, 'You are needed, and you need people,'" Zach Thompson said.

Dosing Initiated in Cohort 2 of the MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic ...

Presentation: First Report of Phase Ib/2a Study Evaluating Safety and Early Efficacy of TN-201, an Adeno-Associated Virus Serotype 9 Gene Replacement Therapy, in Adults with MYBPC3 -Associated ...

ARVC is more common and severe in men, and the researchers discovered that anabolic steroids can make the condition worse, leading to atrial fibrillation. Atrial fibrillation is a condition where the ...

Arrhythmogenic right ventricular cardiomyopathy, or ARVC, is a heart condition caused by a small mutation in someone’s ...

Tenaya’s pipeline includes TN-201, a gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM), TN-401, a gene therapy for PKP2-associated arrhythmogenic right ventricular ...

Tenaya Therapeutics (NASDAQ:TNYA – Free Report) had its price target trimmed by Chardan Capital from $18.00 to $9.00 in a ...